ClinicalTrials.gg
CompletedNCT01565928Updated Apr 22, 2019Results posted

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

A Phase 1 interventional study of MDV3100 in Prostate Cancer, sponsored by Pfizer. Completed at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-22.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
100th of 125
23 · median 52
Started
2012
with 4 others
Phase 1
22 of 125
2 open now
Registered
9th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 100th largest by enrollment, is one of 5 that started in 2012, is one of 22 in phase 1, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • docetaxel
  • MDV3100
  • enzalutamide
  • Xtandi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide ;
  • Men, 18 years of age or older;
  • or cytologically confirmed adenocarcinoma of the prostate;
  • Ongoing androgen deprivation therapy

Exclusion criteria

Exclusion Criteria:

  • Severe concurrent disease;
  • Known or suspected ;
  • History of another within the previous 5 years;
  • Prior treatment with docetaxel-based chemotherapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    MDV3100

    Drug: MDV3100

Interventions

  • 4 x 40 mg capsules, orally, once per day

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2

    Percentage of participants that required dose reductions of Docetaxel and Enzalutamide treatment were reported in this outcome measure. Dose modifications (interruptions or dose reductions) were permitted for participants who had adverse events that were intolerable or could not be improved by other means. Dose reductions or delays were determined according to the prescribing information and at the discretion of the investigator.

    Time frame: Treatment Period 1 (Day 1) up to end of Treatment Period 2 (42 days)

  2. Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)

    AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Percentage of participants that discontinued study drug due to adverse events were reported in this outcome measure.

    Time frame: Treatment Period 1 (Day 1) up to end of study treatment (maximum 70 months)

Secondary outcomes

  1. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Criteria:1)systolic blood pressure (SBP):a) absolute result(AR)\>=180millimeters of mercury(mmHg) and increase from baseline(BL)greater than(\>)40mmHg,b)less than(\<)90mmHg and decrease from BL\>30mmHg,c)most extreme post-BL result\>=140mmHg,d)most extreme post-BL result\>=180mmHg,e)most extreme result(MER)\>=180mmHg and \>=20mmHg change from BL,f)MER\>=140mmHg and \>=20mmHg change from BL;2)diastolic blood pressure(DBP):a)AR\>105mmHg and increase from BL,b)AR\<50mmHg and decrease from BL\>20mmHg;c)most extreme post-BL result\>=90mmHg,d)MER\>=90mmHg and \>=15mmHg change from BL,e)most extreme post-BL result\>=105mmHg,f)MER\>=105mmHg and\>=15mmHg change from BL;3)heart rate:a)AR\>120 beats per minute(bpm) and increase from BL\>30bpm,b) AR\<50 bpm and decrease from BL\>20bpm.Only those categories in which at least 1 participant had clinically significant vital sign abnormality, were reported in this outcome measure.T1 = Timeframe for "Combination Therapy" and T2 = Time frame for "Post-Docetaxel Enzalutamide".

    Time frame: T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5

  2. Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG)

    Clinically significant changes from baseline in ECG findings was based up on investigator's discretion. T1 = Timeframe for "Combination Therapy: Docetaxel 75 mg/m\^2+ Enzalutamide 160 mg" and T2 = Time frame for "Post-Docetaxel Enzalutamide 160 mg".

    Time frame: T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5

  3. Maximum Plasma Concentration (Cmax) of Docetaxel With and Without Enzalutamide Treatment

    Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Docetaxel With and Without Enzalutamide Treatment

    AUClast was observed using a linear mixed-effects model.

    Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2

  5. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of Docetaxel With and Without Enzalutamide Treatment

    AUCinf was observed using a linear mixed-effects model.

    Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2

07

Results

Posted Apr 22, 2019

Participant flow

Participant flow — Overall Study
MilestoneDocetaxel 75 mg/m^2+ Enzalutamide 160 mg
Started22
Completed0
Not completed22
Withdrew: Adverse event3
Withdrew: Other3
Withdrew: Progressive disease13
Withdrew: Withdrawal by subject1
Withdrew: Death2

Outcome measures

PrimaryPercentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2

Percentage of participants that required dose reductions of Docetaxel and Enzalutamide treatment were reported in this outcome measure. Dose modifications (interruptions or dose reductions) were permitted for participants who had adverse events that were intolerable or could not be improved by other means. Dose reductions or delays were determined according to the prescribing information and at the discretion of the investigator.

Time frame:
Treatment Period 1 (Day 1) up to end of Treatment Period 2 (42 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2
percentage of participantsCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Docetaxel Dose Reductions4.5
Enzalutamide Dose Reductions0.0
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)

AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Percentage of participants that discontinued study drug due to adverse events were reported in this outcome measure.

Time frame:
Treatment Period 1 (Day 1) up to end of study treatment (maximum 70 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)
percentage of participantsDocetaxel 75 mg/m^2+ Enzalutamide 160 mg
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)9.1
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Criteria:1)systolic blood pressure (SBP):a) absolute result(AR)\>=180millimeters of mercury(mmHg) and increase from baseline(BL)greater than(\>)40mmHg,b)less than(\<)90mmHg and decrease from BL\>30mmHg,c)most extreme post-BL result\>=140mmHg,d)most extreme post-BL result\>=180mmHg,e)most extreme result(MER)\>=180mmHg and \>=20mmHg change from BL,f)MER\>=140mmHg and \>=20mmHg change from BL;2)diastolic blood pressure(DBP):a)AR\>105mmHg and increase from BL,b)AR\<50mmHg and decrease from BL\>20mmHg;c)most extreme post-BL result\>=90mmHg,d)MER\>=90mmHg and \>=15mmHg change from BL,e)most extreme post-BL result\>=105mmHg,f)MER\>=105mmHg and\>=15mmHg change from BL;3)heart rate:a)AR\>120 beats per minute(bpm) and increase from BL\>30bpm,b) AR\<50 bpm and decrease from BL\>20bpm.Only those categories in which at least 1 participant had clinically significant vital sign abnormality, were reported in this outcome measure.T1 = Timeframe for "Combination Therapy" and T2 = Time frame for "Post-Docetaxel Enzalutamide".

Time frame:
T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mgPost-Docetaxel Enzalutamide 160 mg
SBP: AR- > 180 mmHg, increase from BL > 40 mmHg01
SBP: AR- < 90 mmHg, decrease from BL > 30 mmHg10
SBP: Most extreme post- BL result >= 140 mmHg107
SBP: Most extreme post- BL result >= 180 mmHg02
SBP: MER >= 180 mmHg, >= 20 mmHg change from BL02
SBP: MER >= 140 mmHg, >= 20 mmHg change from BL55
DBP: Most extreme post-BL result >= 90 mmHg36
DBP: Most extreme post-BL result >= 105 mmHg01
DBP: MER >= 105 mmHg,>= 15 mmHg change from BL01
DBP: MER >= 90 mmHg,>= 15 mmHg change from BL14
Heart Rate: AR >120 bpm, increase from BL >30 bpm01
Heart Rate: AR <50 bpm, decrease from BL >30 bpm01
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG)

Clinically significant changes from baseline in ECG findings was based up on investigator's discretion. T1 = Timeframe for "Combination Therapy: Docetaxel 75 mg/m\^2+ Enzalutamide 160 mg" and T2 = Time frame for "Post-Docetaxel Enzalutamide 160 mg".

Time frame:
T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG)
ParticipantsCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mgPost-Docetaxel Enzalutamide 160 mg
Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG)10
SecondaryMaximum Plasma Concentration (Cmax) of Docetaxel With and Without Enzalutamide Treatment
Time frame:
Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
Reported as:
Geometric mean · nanograms per milliliter
Maximum Plasma Concentration (Cmax) of Docetaxel With and Without Enzalutamide Treatment
nanograms per milliliterCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Docetaxel Without Enzalutamide1722.1 ± 27.14
Docetaxel With Enzalutamide1662.9 ± 23.00
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Docetaxel With and Without Enzalutamide Treatment

AUClast was observed using a linear mixed-effects model.

Time frame:
Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
Reported as:
Geometric mean · nanograms*hour per milliliter
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Docetaxel With and Without Enzalutamide Treatment
nanograms*hour per milliliterCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Docetaxel Without Enzalutamide1866.6 ± 29.05
Docetaxel With Enzalutamide1674.4 ± 19.32
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of Docetaxel With and Without Enzalutamide Treatment

AUCinf was observed using a linear mixed-effects model.

Time frame:
Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
Reported as:
Geometric mean · nanograms*hour per milliliter
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of Docetaxel With and Without Enzalutamide Treatment
nanograms*hour per milliliterCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Docetaxel Without Enzalutamide2020.1 ± 27.98
Docetaxel With Enzalutamide1769.1 ± 18.91

Adverse events

Collected over Baseline up to a maximum of approximately Month 12 for Combination Therapy; From Month 10.6 up to a maximum of approximately Month 71.5 for Post-Docetaxel Enzalutamide. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg—8/22 (36.4%)21/22 (95.5%)
Post-Docetaxel Enzalutamide 160 mg—7/21 (33.3%)18/21 (85.7%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mgPost-Docetaxel Enzalutamide 160 mg
ATRIAL FIBRILLATIONCardiac disorders0/223/21
FEBRILE NEUTROPENIABlood and lymphatic system disorders3/220/21
ACUTE CORONARY SYNDROMECardiac disorders2/220/21
ATRIAL FLUTTERCardiac disorders0/221/21
CARDIAC FAILURE ACUTECardiac disorders0/221/21
CARDIAC FAILURE CONGESTIVECardiac disorders0/221/21
ASTHENIAGeneral disorders0/221/21
IMPAIRED HEALINGGeneral disorders0/221/21
PYREXIAGeneral disorders1/221/21
CELLULITISInfections and infestations0/221/21
Most frequent other events
Showing 10 of 151
Most frequent other events
EventCombination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mgPost-Docetaxel Enzalutamide 160 mg
NEUTROPENIABlood and lymphatic system disorders19/221/21
FATIGUEGeneral disorders16/225/21
NEUROPATHY PERIPHERALNervous system disorders10/221/21
CONSTIPATIONGastrointestinal disorders7/229/21
NAUSEAGastrointestinal disorders9/221/21
BACK PAINMusculoskeletal and connective tissue disorders8/225/21
PERIPHERAL SENSORY NEUROPATHYNervous system disorders7/224/21
DECREASED APPETITEMetabolism and nutrition disorders5/226/21
DIARRHOEAGastrointestinal disorders6/220/21
ARTHRALGIAMusculoskeletal and connective tissue disorders6/224/21

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Mean68.0 ± 10.66
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Female0
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
Hispanic or Latino0
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Docetaxel 75 mg/m^2+ Enzalutamide 160 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White19
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jul 2013, 17 months.

Results were first posted in Apr 2019, 5 years 9 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 17 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2012
First posted
Mar 29, 2012
StartActual
Jan 24, 2012
Primary completionActual
Jul 1, 2013
CompletionActual
Feb 26, 2018
Results first posted
Apr 22, 2019
Last update
Apr 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01565928
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Jan 24, 2012
Primary completion
Jul 1, 2013
Completion
Feb 26, 2018
Results posted
Apr 22, 2019
Last update
Apr 22, 2019

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion